WELCOME TO HEP DART 2023

Hacienda del mar, Los Cabos, Mexico / 3-7 December 2023

We are pleased to announce Hep DART 2023 will be held at the Hacienda Del Mar from December 3-7, 2023 in Cabo San Lucas, Mexico.

After the conference in 2021 we sent a survey out to the former participants of Hep DART to assess were the delegates would like to hold the conference. We received an overwhelming response to continue to hold the conference in Cabo San Lucas. Cabo is an ideal location to hold a conference in December. The climate is warm with little chance of rain during that time of the year. This allows us to hold many events outdoors and provide ample space for social distancing. Additionally, the Cabo is a centralized location for international delegates while allowing additional visa access.

The DART series is and in-person meeting designed for vibrant scientific presentations and discussion, as well as for new investigators to meet leaders in their field, benefiting from educational feedback on their work.

The aim of HEP DART 2023 is to assemble clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). This CME-accredited workshop will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer.

We hope to see you in December!

History of HEP DART: Frontiers in Drug Development for Hepatology

Since its inception in 1995, HEP DART has provided a cutting-edge platform for tackling challenges in drug development for viral hepatitis and chronic liver disease. Hep DART has been held in-person every other year at various locations. HEP DART assembles clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC).

HEP DART 2023: Organizing Committee

Raymond F. Schinazi

Emory University, USA

Mark Sulkowski

Johns Hopkins University, USA

Manal El-Sayed

Ain Shams University, Egypt

Eugene Schiff

University of Miami, United States

Andrea Cox

Johns Hopkins Medicine United States

Charles Rice

Rockefeller University United States

Hep DAR2023: Scientific Committee

  • Harvey Alter, NIH, USA

  • Ralf Bartenschlager, University of Heidelberg, Germany

  • Mithat Bozdayi, Ankara University, Turkey

  • Carol Brosgart, University of California, San Francisco, USA

  • Francis Chisari, The Scripps Research Institute, USA

  • Adrian Di Bisceglie, Saint Louis University, USA

  • Geoffrey Dusheiko, University College London, UK

  • Jordan Feld, Toronto General Hospital, Canada

  • Michael Fried, University of North Carolina, USA

  • Robert Gish, Robert G. Gish Consultants, LLC, USA

  • Jason Grebely, University of New South Wales, Australia

  • Brent Korba, Georgetown University, USA

  • Shyamasundaran Kottilil, Maryland University, USA

  • George Lau, Humanity and Health Medical Center, Hong Kong, China

  • Stanley Lemon, University of North Carolina, at Chapel Hill, USA

  • Miriam Levy, University of Western Sydney & University of New South Wales, Australia

  • Michael Manns, Hannover Medical School, Germany

  • Patrick Marcellin, Hopital Beaujon, France

  • Marion Peters, University of California, San Francisco, USA

  • Ulrike Protzer, Technical University of Munich, Germany

  • Harry Janssen, Erasmus Medical Center, the Netherlands

The Committees of HEP-DART consist of experts with a tremendous amount of experience and knowledge in the field of hepatology.  

Plenary Lectures from

Norah Terrault

University of Southern California, USA

Ralf Bartenschalger

University of Heidelberg, Germany

Helene Strick-Marchand

Pasteur Institute, France

George Lau

Humanity and Health Medical Group, Hong Kong

Manal El-Sayed

Ain Shams University, Egypt

Stephan Urban

University of Heidelberg, Germany

Fabien Zoulim

University of Lyon, France

Geoff Dusheiko

Kings College Hospital, United Kingdom

Scientific Program

40+ World-class invited key opinion leaders

CME accreditation

5 days of scientific programming 

No concurrent sessions

Academic and Industry sessions

5 Panel discussions + 1 debate

1 poster session with poster review

12+ Hours dedicated to networking

To stay up to date on the latest speakers please sign-up for our mailing list

HEP DART 2023: Registration

Hep-DART 2023 to be held December 3rd-7th, 2023 at the Hacienda del Mar (a Marriott company)

Los Cabos, Mexico

Hotel rooms available at a significantly discounted price for the conference. Available during the conference and 4 nights pre and post conference.

Rates starting at $199++

For additional information, please reach us at info@ihorizonsed.com

Fees and Deadlines

  • Special rate for students, post-docs, and nurses* - $1,000

  • Academic/Government/Non-Profit Registration - $1,200

  • Industry Registration - $1,700

  • * Resource-Limited Settings: We offer special discounts to all community representatives, NGO representatives, and healthcare professionals from resource limited settings. Please email us at info@hepdart.com for more information.

  • *Deadline to register in November 20th, 2023

Registration package includes

  • Access to all meeting sessions

  • Access to conference App and electronic abstract book

  • Official conference materials and T-shirt

  • Welcome reception

  • 4 breakfasts (Monday-Thursday)

  • 3 lunches (Monday-Wednesday)

  • AM and PM coffee breaks for the duration of the meeting

  • Poster reception

  • Closing dinner

  • Heavily discounted hotel room rates

*terms and conditions*

Important Dates

Monday, June 19, 2023: 
Early registration is open 

Monday, July 17, 2023: 
Early registration deadline at 11:59 EST pm US Eastern Time

Monday, October 2, 2023: 
Regular registration deadline at 11:59 EST pm US Eastern Time

Monday, October 2, 2023: 
Abstract submission deadline at 11:59 EST pm US Eastern Time

Monday, October 2, 2023: 
Scholarship application deadline at 11:59 EST pm US Eastern Time

Monday, November 20, 2023: 
Late registration deadline at 11:59 pm US Eastern Time 

Sunday, December 03, 2023: 
HEP-DART 2023 meeting will start at 4:00 pm US Mountain Standard Time 

Thursday, December 07, 2023: 
HEP-DART 2023 meeting adjourns at 12:00 pm US Mountain Standard Time

Meeting Ojectives

Understand the role of viral targets in the drug development and discovery process

Identify the next generation of inhibitors of viral hepatitis (HAV, HBV, HCV, HDV, HEV), NASH and HCC

Describe the latest developments in HCV, HDV, and HBV therapeutics

Road to HBV Cure

Assess the impact of resistance and treatment failure in the drug development and discovery process

Understand the role of hepatic cells in viral pathogenesis

Understand immune status and the viral genetics of viral hepatitis

Review current treatment guidelines for HCV and HBV in adults and children

Increase awareness of the clinical impact of antiviral agents

Understand the consequences of NASH and co- infections with HIV on the management of patients

Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and co-infections with HIV

Understand the transmission of viral hepatitis

Describe novel genetic markers for HCV and HBV disease and treatment

Understand the demographic and ecologic conditions that favor the spread of viral hepatitis in various populations including prisons and people who use drugs.

Understand the obstacles to access to treatment and preventive methods

Determine the economic impact of HCV and HBV therapeutics

Provide recommendations for a global blueprint for “Seek, Test, Treat and Eradicate” efforts